Xenial Pharma

Xenial Pharma is a clinical-stage biotechnology company dedicated to developing innovative therapies for patients with rare endocrine and metabolic diseases. The company's lead program, XN-101 (pexacerfont), is a potent and selective oral CRF1 receptor antagonist currently being evaluated for the treatment of Congenital Adrenal Hyperplasia (CAH). Xenial aims to address the significant unmet medical needs in CAH by providing a non-steroidal approach to managing androgen excess and reducing the burden of chronic glucocorticoid therapy. The leadership team consists of experienced industry veterans with a track record in rare disease drug development and commercialization. The company is headquartered in Bridgewater, New Jersey, and focuses on advancing its pipeline through strategic licensing and internal development.